Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Accumulated Expenses (2021 - 2022)

Senti Biosciences has reported Accumulated Expenses over the past 2 years, most recently at $4.0 million for Q1 2022.

  • Quarterly results put Accumulated Expenses at $4.0 million for Q1 2022, up 396732.4% from a year ago — trailing twelve months through Mar 2022 was $4.0 million (up 396732.4% YoY), and the annual figure for FY2021 was $3.1 million, changed.
  • Accumulated Expenses for Q1 2022 was $4.0 million at Senti Biosciences, up from $3.1 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for SNTI hit a ceiling of $4.0 million in Q1 2022 and a floor of $1000.0 in Q1 2021.